non-small cell lung cancer
Conditions
Interventions
one:EGFR-TKIs targeted therapy was accepted
Sponsors
Meizhou People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients must meet all of the following inclusion criteria to be enrolled in this study: 1. Older than or equal to 18 years of age, younger than or equal to 75 years of age, male or female; 2. Non-small cell lung cancer was pathologically confirmed with EGFR gene sensitive mutation, and EGFR-TKIS targeted therapy was planned; 3. Chronic HBV infection: HBsAg and/or HBV-DNA positive, ALT normal; 4. If there is no prior palliative chemotherapy or immunotherapy, prior adjuvant chemotherapy or immunotherapy is allowed to be enrolled, but the end of adjuvant chemotherapy or adjuvant immunotherapy is required to be more than 6 months from the beginning of the study observation, and the end of adjuvant immunotherapy is required to be more than 12 months from the beginning of the study observation; 5. Life expectancy >=3 months; 6. Understand and voluntarily participate in the study and sign the informed consent.
Exclusion criteria
Exclusion criteria: Patients with any of the following conditions cannot be enrolled in this study: 1. A history of acute or severe hepatitis; 2. Previous anti-hepatitis B treatment; 3. Complicated with other types of hepatitis virus infection (hepatitis A, c, etc.); 4, combined with immune diseases or long-term oral immunosuppressants; 5. Any other obvious clinical manifestations or laboratory abnormalities preclude the patient from participating in the clinical study; 6. decompensated fatty liver, alcoholic liver, cirrhosis, biliary diseases, etc.; 7. Using other drugs that may cause hbV-DNA reactivation, such as hormones; 8. Pregnancy or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV-DNA;therapy and response criteria evaluation; | — |
Countries
China
Contacts
Public ContactGuowu Wu
Outcome results
None listed